Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alkotinib in Advanced ALK+/ROS1+ NSCLC
NCT03607188Phase 1Completed
- Sponsor
- Zelgen
- Start
- Oct 2018
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of alkotinib in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Zelgen. Primary endpoint: Maximum Tolerated Dose. Started Oct 2018; status: completed.
02
Drugs
alkotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03607188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03607188.